A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure (vol 143, pg 325, 2014)

Massarweh Suleiman; Romond Edward; Black Esther P.; Van Meter Emily; Shelton Brent; Kadamyan-Melkumian Vera; Stevens Mark; Elledge Richard

首页> 外文期刊>Breast cancer research and treatment. >A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure (vol 143, pg 325, 2014)

【24h】

A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure (vol 143, pg 325, 2014)

机译：芳香酶抑制剂（AI）失效后转移性雌激素受体（ER）阳性乳腺癌患者中氟维司群和依维莫司联合治疗的II期研究（第143卷，第325页，2014年）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Breast cancer research and treatment.》 |2015年第2期|共1页
作者
Massarweh Suleiman; Romond Edward; Black Esther P.; Van Meter Emily; Shelton Brent; Kadamyan-Melkumian Vera; Stevens Mark; Elledge Richard;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure (vol 143, pg 325, 2014) [J] . Massarweh Suleiman, Romond Edward, Black Esther P., Breast cancer research and treatment. . 2015,第2期

机译：芳香酶抑制剂（AI）失效后转移性雌激素受体（ER）阳性乳腺癌患者中氟维司群和依维莫司联合治疗的II期研究（第143卷，第325页，2014年）
2. RETROSPECTIVE STUDY OF EVEROLIMUS WITH FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER PRETREATED WITH AROMATASE INHIBITORS(AI'S) AND SELECTIVE ESTROGEN MODIFIERS [J] . Vanacker Leen The Breast : . 2015,第Suppla3期

机译：芳香胺抑制剂和选择性雌激素修饰的激素受体阳性转移性乳腺癌的绝经后妇女中雌花不齐的回顾性研究
3. RETROSPECTIVE STUDY OF EVEROLIMUS WITH FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER PRETREATED WITH AROMATASE INHIBITORS(AI'S) AND SELECTIVE ESTROGEN MODIFIERS [J] . Vanacker Leen The Breast : . 2015,第Suppla3期

机译：用芳香糖酶抑制剂（AI's）和选择性雌激素改性剂预处理促血管蛋白酶阳性转移性乳腺癌前代妇女血尿血症血尿症的回顾性研究
4. Study on Molecular Docking of Red Betel (Piper Crocatum Ruiz Pav.) Active Compound and Tamoxifen Drug as an Inhibitor of Estrogen Receptor-α (ER-α) that Plays a Role in Breast Cancer [C] . Siti Imroatul Maslikah, Sri Rahayu Lestari, Nursasi Handayani, International Conference on Life Sciences and Technology . 2020

机译：红色槟榔（吹笛茶叶ruiz＆pav.）活性化合物和三氧化物药物作为发挥乳腺癌作用的雌激素受体-α（ER-α）抑制剂的研究
5. Overcoming Anti-Estrogen Resistance in Estrogen Receptor (ER)-Positive Breast Cancer: Rational Targeting of Phosphatidylinositol 3-Kinase (PI3K) and the Resurrection of Estrogen Therapy [D] . Hosford, Sarah 2018

机译：克服雌激素受体（ER）阳性乳腺癌中的抗雌激素抵抗：磷脂酰肌醇3-激酶（PI3K）的合理靶向和雌激素疗法的复活
6. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102 [O] . Noah Kornblum, Fengmin Zhao, Judith Manola, -1

机译：孕激素受体阳性人表皮生长因子受体2阴性对芳香化酶抑制剂治疗有抵抗力的转移性乳腺癌的女性绝经后妇女加用舒尔美司特加依维莫司或安慰剂的II期随机试验：PrE0102的结果
7. Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure [O] . Suleiman Massarweh, Edward Romond, Esther P. Black, 2015

机译：勘误表：芳香酶抑制剂（AI）失败后转移性雌激素受体（ER）阳性乳腺癌患者组合氟斯特朗司和血尿症患者的II期研究

A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure (vol 143, pg 325, 2014)

著录项

相似文献

相关主题

期刊订阅